Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMD NASDAQ:DHAI NASDAQ:INBS NASDAQ:LYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.20+4.3%$2.23$1.10▼$8.44$2.97M1.69222,694 shs1.01 million shsDHAIDIH Holding US$0.24-5.4%$0.23$0.12▼$3.39$11.83M0.07895,134 shs435,028 shsINBSIntelligent Bio Solutions$1.90+9.8%$1.60$1.00▼$3.00$11.95M4.6567,059 shs808,534 shsLYRALyra Therapeutics$8.48-2.6%$9.99$3.81▼$37.50$11.54M0.24192,235 shs25,955 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+4.35%+0.84%-31.82%-57.29%-64.54%DHAIDIH Holding US-5.44%+1.03%+6.97%+34.70%-92.35%INBSIntelligent Bio Solutions+9.83%+11.11%-0.52%+58.33%-1.55%LYRALyra Therapeutics-2.64%-8.32%-25.22%+84.35%-44.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical1.9197 of 5 stars3.02.00.00.02.70.01.3DHAIDIH Holding US0.6674 of 5 stars0.02.00.00.03.81.70.0INBSIntelligent Bio Solutions0.8266 of 5 stars0.03.00.00.02.60.01.3LYRALyra Therapeutics2.6742 of 5 stars3.22.00.00.02.42.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 2.00Hold$56.004,566.67% UpsideDHAIDIH Holding US 0.00N/AN/AN/AINBSIntelligent Bio Solutions 0.00N/AN/AN/ALYRALyra Therapeutics 2.33Hold$100.001,079.25% UpsideCurrent Analyst Ratings BreakdownLatest AEMD, INBS, LYRA, and DHAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K5.45N/AN/A$2.55 per share0.47DHAIDIH Holding US$64.47M0.17N/AN/A($0.80) per share-0.30INBSIntelligent Bio Solutions$3.11M4.22N/AN/A$2.37 per share0.80LYRALyra Therapeutics$1.53M7.37N/AN/A$8.86 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$13.39M-$12.64N/AN/AN/AN/A-221.38%-156.83%8/13/2025 (Estimated)DHAIDIH Holding US-$8.44M-$0.30N/A∞N/A-13.59%N/A-25.97%N/AINBSIntelligent Bio Solutions-$10.16MN/A0.005.43N/A-319.85%-176.55%-93.89%9/17/2025 (Estimated)LYRALyra Therapeutics-$93.43M-$60.50N/AN/AN/A-6,711.39%-295.52%-66.95%8/13/2025 (Estimated)Latest AEMD, INBS, LYRA, and DHAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025LYRALyra Therapeutics-$7.50-$6.00+$1.50-$0.13$0.16 million$0.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/ADHAIDIH Holding USN/AN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.133.13DHAIDIH Holding USN/A0.510.34INBSIntelligent Bio SolutionsN/A1.120.97LYRALyra TherapeuticsN/A2.962.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%DHAIDIH Holding US27.76%INBSIntelligent Bio Solutions32.97%LYRALyra Therapeutics95.62%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical1.20%DHAIDIH Holding US49.58%INBSIntelligent Bio Solutions0.28%LYRALyra Therapeutics3.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical102.59 million2.55 millionNo DataDHAIDIH Holding USN/A47.34 million23.87 millionN/AINBSIntelligent Bio Solutions106.91 million6.89 millionNot OptionableLYRALyra Therapeutics501.33 million1.28 millionOptionableAEMD, INBS, LYRA, and DHAI HeadlinesRecent News About These CompaniesLyra Therapeutics, Inc. (NASDAQ:LYRA) CEO Maria Palasis Sells 1,565 SharesJuly 15 at 4:46 AM | americanbankingnews.comLyra Therapeutics, Inc. (NASDAQ:LYRA) CEO Sells $13,944.15 in StockJuly 15 at 4:42 AM | insidertrades.comLyra Therapeutics (NASDAQ:LYRA) Stock Rating Lowered by Wall Street ZenJuly 13 at 2:26 AM | americanbankingnews.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and Warrants - NasdaqJune 29, 2025 | nasdaq.comLyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%June 27, 2025 | msn.comLyra Therapeutics, Inc. Announces Definitive Agreement for Registered Direct Offering and Private Placement of Common Stock and WarrantsJune 27, 2025 | quiverquant.comQLyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq RulesJune 27, 2025 | globenewswire.comLyra Therapeutics Regains Nasdaq Compliance in June 2025June 23, 2025 | tipranks.comLyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated CatalystJune 16, 2025 | seekingalpha.comLyra Therapeutics (LYRA) Upgraded to Buy: Here's WhyJune 12, 2025 | zacks.comH.C. Wainwright lifts Lyra Therapeutics stock target to $16June 11, 2025 | investing.comLyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study SuccessJune 5, 2025 | zacks.comLyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in ...June 4, 2025 | seekingalpha.comLyra Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:LYRA | BenzingaJune 3, 2025 | benzinga.comLyra Therapeutics (NASDAQ:LYRA) Stock, Insider Trading ActivityJune 3, 2025 | benzinga.comAsian markets rise as US stocks near records on easing trade tensionsJune 2, 2025 | business-standard.comBLyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s ThrilledJune 2, 2025 | msn.comWall Street drifts higher as oil prices jump and US manufacturing slumpsJune 2, 2025 | msn.comWhy Did Lyra Therapeutics’ Stock Rocket Past 440% in Premarket TodayJune 2, 2025 | tokenist.comTLyra Therapeutics Shares Skyrocket on Strong Phase 3 Results for CRS TreatmentJune 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAEMD, INBS, LYRA, and DHAI Company DescriptionsAethlon Medical NASDAQ:AEMD$1.20 +0.05 (+4.35%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.18 -0.02 (-2.08%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.DIH Holding US NASDAQ:DHAI$0.24 -0.01 (-5.44%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$0.24 0.00 (-0.59%) As of 07/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.Intelligent Bio Solutions NASDAQ:INBS$1.90 +0.17 (+9.83%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.92 +0.02 (+1.05%) As of 07/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Lyra Therapeutics NASDAQ:LYRA$8.48 -0.23 (-2.64%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$8.45 -0.03 (-0.35%) As of 07/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
